Alverine: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: April 10, 2026🚩 Report this page

Alverine

Other Drugs For Functional Gastrointestinal Disorders

GB MHRA

Drug class: Other Drugs For Functional Gastrointestinal Disorders
Availability: See label
Markets covered: 1
Products on record: 15

A03AXOther Drugs For Functional Gastrointestinal Disorders

Overview

Alverine is an active pharmaceutical ingredient in the Other Drugs For Functional Gastrointestinal Disorders group (A03AX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	15	April 10, 2026

GBUnited Kingdom· MHRA

15 products

Uses

GBOfficial regulatory label· revised December 5, 2025[1]

Alverine Citrate 120 mg capsules is indicated for the relief of smooth muscle spasm, in conditions such as irritable bowel syndrome, painful diverticular disease of the colon and primary dysmenorrhoea.

How to take

Sources & citations

[1]MHRA (UK) · PL440410120 · revised December 5, 2025

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised December 5, 2025[1]

Within the system organ classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: Very common (≥1/10); Common (≥1/100 to <1/10); Uncommon (≥1/1,000 to <1/100); Rare (≥1/10,000 to <1/1,000); Very rare (<1/10,000); Not known (cannot be estimated from the available data) The following undesirable effects were observed: Immune system disorders Not known: anaphylaxis, allergic reaction Nervous system disorders Not known: dizziness, headache Respiratory, thoracic and mediastinal disorders Not known: dyspnoea and/or wheezing Gastrointestinal disorders Not known: Nausea Hepatobiliary disorders Not known: jaundice due to hepatitis (typically resolves on cessation of Alverine), liver function test abnormal Skin and subcutaneous tissue disorders Not known: rash, itching Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised December 5, 2025[1]

Additional warnings to be included in the Patient Information Leaflet:
If this is the first time you have had these symptoms, consult your doctor before using any treatment. If any of the following apply do not use Alverine citrate 120 mg Capsules; it may not be the right treatment for you. See your doctor as soon as possible if: - you are aged 40 years or over - you have passed blood from the bowel - you are feeling sick or vomiting - you have lost your appetite or lost weight - you are looking pale and feeling tired - you are suffering from severe constipation - you have a fever - you have recently travelled abroad - you are or may be pregnant - you have abnormal vaginal bleeding or discharge - you have difficulty or pain passing urine.
Consult your doctor if you have developed new symptoms, or if your symptoms worsen, or if they do not improve after 2 weeks treatment.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drugs in the same class

Sources & citations